Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH website updates and a change in terminology from “Artificial Intelligence” to “Super Intelligence.” The site revision label changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T23:42:10.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1; the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-07T00:13:56.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden message instead of the study details, making the record inaccessible to users visiting the page.
    Difference
    19%
    Check dated 2026-09-23T01:05:19.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The revision tag was updated from v3.6.6 to v3.7.0, indicating a deployment update; no study content changes are introduced.
    Difference
    0.1%
    Check dated 2026-09-16T00:15:09.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    Revision updated from v3.6.5 to v3.6.6, indicating a small update to the site's underlying system.
    Difference
    0.1%
    Check dated 2026-09-01T19:33:48.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.6.5, replacing the previous v3.6.4; this appears to be a software version update with no visible changes to study details or content.
    Difference
    0.1%
    Check dated 2026-08-11T16:35:41.000Z thumbnail image

Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.